ESCRS - PP25.05 - Clinical Impact Of Residual Astigmatism In Patients With A Novel Presbyopia-Correcting Intraocular Lens

Clinical Impact Of Residual Astigmatism In Patients With A Novel Presbyopia-Correcting Intraocular Lens

Published 2022 - 40th Congress of the ESCRS

Reference: PP25.05 | Type: Free paper | DOI: 10.82333/fqjj-h369

Authors: Laureano Rementeria* 1 , Javier Ruiz Alcocer 2

1Medical director,Clinica Rementería,Madrid,Spain, 2Profesor,Universidad Complutense de Madrid,Madrid,Spain

Purpose

To analyze the tolerance to residual astigmatic refractive errors in patients using a novel presbyopia-correcting extended vision intraocular lens (IOL).

Setting

Clínica Rementería, Madrid, Spain

Methods

This prospective case series study considered patients with the Acrysof® IQ Vivity® IOL with a postoperative residual refractive error ≤ ±0.25D and an uncorrected distance visual acuity of at least 0.0 logMAR (1.0 decimal) three months after the surgery (initial status). Distance and intermediate VA at 66cm were also measured with a residual mixed astigmatism induced by adding a combination of -0.25 diopter (D) spherical and 0.50 D cylindrical lenses placed in vertical (against the rule - ATR), oblique and horizontal (with the rule – WTR) positions.

Results

A total of 20 eyes of 20 patients were included. At distance, the VA for the reference situation was -0.05±0.05 logMAR while VA values for the ATR, oblique and WTR astigmatism simulations were 0.00±0.05, -0.01±0.04 and 0.00±0.04 logMAR, respectively. Distance VA was better at the initial status (p<0.001) and no differences were found among the three astigmatic simulations (p=0.19). The statistical difference for the initial status was not significant at a clinical level. Intermediate VA values at the initial situation, ATR, oblique and WTR situations were 0.09±0.07, 0.10±0.07, 0.10±0.06 and 0.11±0.06 logMAR, respectively, with no differences among them (p=0.16). 

Conclusions

Low residual mixed astigmatisms, regardless their orientation, seem to be tolerated in patients with the IOL under study both for distance and intermediate distances.